Since the previous Commissoner resigned, rumors have been accumulating regarding names of successors to this important position, which in fact oversees 25% of the US Economy as either food or drugs.
The Wallstreet Journal website broke the news, and all of this is expected to become official within the coming days.
Joshua Sharfstein will probably be named as Hamburg's deputy commissioner, also to be announced formally within the coming days.
Hamburg will have a heap of work ahead of her because of obvious short-comings when it comes to the FDA's functioning effectiveness. Outbreaks of food born illnesses have caused many to lose all faith in the FDA which is given by 1937 statute the task of protecting America from such situations. Hamburg is qualified for the position as leader of the FDA, having worked previously as a bioterrorism expert, serving during the Clinton Administration.
Details in this statement written by Dr. Hamburg:Inspiration
Both my parents are physicians. I grew up right on the Stanford campus, surrounded by many friends and families that were related to the field of medicine... so it was always part of part of my experience. But because it was so much a part of my experience, I did have to go through the re-thinking: Is this something I really want to do, or was I just raised to think that of course I would be a doctor?
Biography
Margaret Hamburg, one of the youngest people ever elected to the Institute of Medicine (IoM, an affiliate of the National Academy of Sciences), is a highly regarded expert in community health and bio-defense, including preparedness for nuclear, biological, and chemical threats. As health commissioner for New York City from 1991 to 1997, she developed innovative programs for controlling the spread of tuberculosis and AIDS.
Margaret Hamburg is the daughter of Beatrix and David Hamburg, both distinguished physicians and early role models for her career in medicine. Her mother was the first African-American woman to attend Vassar College and to earn a degree from the Yale University School of Medicine (which had previously excluded black students). Her Jewish father and grandmother taught her to value education and family and to fight discrimination and oppression.
When she was inducted into the prestigious Institute of Medicine in 1994, she had followed the path of her parents, both IoM members since the 1970s. "There was a sense of real fun that the father-mother-daughter constellation had been formed," said Hamburg.
Hamburg is a graduate of Radcliffe College. She earned her M.D. from Harvard Medical School, and completed her training at the New York Hospital/Cornell University Medical Center. She did research in neuroscience at Rockefeller University in New York from 1985 to1986 and in neuropharmacology (the study of the action of drugs on the nervous system) at the National Institute of Mental Health in Bethesda, Maryland.
From 1986 to 1988, she served in the U.S. Office of Disease Prevention and Health Promotion, and from 1989 to 1990 she was assistant director of the National Institute of Allergy and Infectious Diseases at NIH, where her work focused on AIDS research.
In 1990, she left the NIH to serve as deputy health commissioner for New York City. Within a year, she was promoted to health commissioner. It was a difficult, complex, and demanding job, with severe budget constraints and many responsibilities, ranging from clinical services to environmental health. She strove to improve health services for women and children, instituted needle-exchange programs to combat HIV infection, made inroads into curbing the spread of tuberculosis, and initiated the nation's first public-health bio-terrorism defense program. During her term as health commissioner, she also held academic positions at Columbia University School of Public Health and Cornell University Medical College, both in New York City.
While commissioner Dr. Hamburg's innovative treatment plan for tuberculosis (TB) became a model for health departments around the world. In the 1990s, TB was the leading infectious killer of youths and adults and had become resistant to standard drugs. To be effective, new drugs required patients to take pills every day for up to two years, but failure to complete the full course of treatment allowed the bacteria to mutate into drug-resistant strains. Hamburg sent healthcare workers to patients' homes to help manage their drug regimen, and between 1992 and 1997, the TB rate for New York City fell by 46 percent, and by 86 percent for the most resistant strains.
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
1
1
1
